Currus Biologics
Currus Biologics is a pre-clinical biotechnology company pioneering next-generation CAR-T cell therapies for solid tumours. By leveraging its proprietary BEAT platform, Currus aims to overcome the limitations of current CAR-T technologies targeting solid tumours and enable targeted, effective treatment of cancers such as breast, colon, pancreatic, and prostate.
Therapeutic Area:
Immuno-OncologyOncology
Unmet Need and Commercial Potential
Over 10 million people globally are diagnosed with solid tumours each year, yet current immunotherapies—including CAR-T cell treatments—have shown limited success outside of blood cancers.
Currus Biologics’ approach could redefine cancer care by enabling effective CAR-T therapies for solid tumours, offering new hope to patients with few treatment options.
10 million
People diagnosed with solid tumours annually.
Solid tumours, which make up 90% of all cancers.
Investors
